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ABSTRACT 
Nicotine is metabolized into cotinine and then into trans-3’-hydroxycotinine, mainly by cytochrome 
P450 2A6. Recent studies reported better effectiveness of varenicline in women and in nicotine normal 
metabolizers phenotypically determined by nicotine-metabolite ratio. Our objective was to study the 
influence of nicotine-metabolite ratio, CYP2A6 genotype and sex on the response to nicotine 
replacement therapy and varenicline. Data were extracted from a longitudinal study which included 
smokers participating in a smoking cessation program. Response to treatment was defined by the 
absence of relapse when a set threshold of reduction in cigarettes per day relative to the week before 
the study was no more reached. The analysis considered total and partial reduction defined by a 
diminution of 100% and of 90% in cigarettes per day, respectively. The hazard ratio of relapsing was 
estimated in multivariate Cox regression models including the sex and the nicotine metabolism 
determined by the phenotype or by CYP2A6 genotyping (rs1801272 and rs28399433). In the normal 
metabolizers determined by phenotyping and in women, the hazard ratio for relapsing was significantly 
lower with varenicline for a partial decrease (HR=0.33, 95%CI=[0.12-0.89] and HR=0.20, 95%CI=[0.04-
0.91], respectively) and non-significantly lower for a total cessation (HR=0.45, 95%CI=[0.20-1.0] and 
HR=0.38, 95%CI=[0.14-1.0]). When compared to the normal metabolizers determined by phenotyping, 
the hazard ratio for a partial decrease was similar in the normal metabolizers determined by genotyping 
(HR=0.42, 95%CI=[0.18-0.94]) while it was significantly lower with varenicline for a total cessation 
(HR=0.50, 95%CI=[0.26-0.98]). Women and normal nicotine metabolizers may benefit more from 
varenicline over nicotine replacement therapy. 
 
Keywords: Nicotine, varenicline, sex, genetics, nicotine metabolism  
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Public Significance Statements 
This study confirms that varenicline has better effectiveness than nicotine replacement therapy in 
nicotine normal metabolizers determined by the nicotine-metabolite ratio, and in women. The nicotine 
normal metabolizers determined by CYP2A6 rs1801272 genotyping also have greater response to 
varenicline than to nicotine replacement therapy. The choice of the smoking cessation pharmacological 
treatment should take into account nicotine metabolism and sex to obtain better abstinence rate in 
smokers. 
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INTRODUCTION 
Smokers willing to stop smoking may be helped by a pharmacotherapy such as nicotine replacement 
therapy (NRT), bupropion or varenicline. These three medications are used worldwide and several head-
to-head effectiveness comparisons have been performed with mixed results. Varenicline has been 
associated with greater continuous abstinence rates than NRT after 52 weeks of follow-up (Aubin et al., 
2008; Kralikova et al., 2013). A multicenter study including 47 smoking cessation services concluded in a 
small advantage of varenicline over NRT combinations (i.e. any formulations such as gums, spray and/or 
patches) although variations in population characteristics or clinical practice appear to influence the 
effectiveness of both therapies (Brose, West, & Stapleton, 2013). A randomized parallel clinical trial in 
272 subjects reported equivalent success between varenicline and nicotine patches at 1, 6 and 12 
months of follow-up (Heydari, Talischi, Tafti, & Masjedi, 2012), while a meta-analysis concluded that 
varenicline and combined NRT were equally effective in continuous or prolonged abstinence during at 
least 6 months (Cahill, Stevens, Perera, & Lancaster, 2013). 
In humans, nicotine is metabolized into cotinine and then into trans-3’-hydroxycotinine, mainly by 
cytochrome P450 (CYP) 2A6 (Messina, Tyndale, & Sellers, 1997; Nakajima et al., 1996). The nicotine-
metabolite ratio refers to the 3’-hydroxycotinine / cotinine ratio during smoking ad libitum, and is a 
marker of CYP2A6 activity. Interestingly, nicotine-metabolite ratio seems to be associated with 1-week 
abstinence, with nicotine slow metabolizers being more likely to achieve abstinence than normal 
metabolizers (odds ratio [OR] = 1.32, 95% confidence interval [CI] = 1.05, 1.67; P = .019) (Chenoweth et 
al., 2015). Furthermore, a recent double-blind placebo-controlled trial reported that varenicline had 
greater effectiveness than NRT in nicotine normal metabolizers as determined by the nicotine-
metabolite ratio (Lerman et al., 2015).  
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Compared to CYP2A6 genotyping, nicotine-metabolite ratio has the advantage of taking into account 
both genetic and environmental (eg. oestrogen) effects on CYP2A6 activity (Dempsey et al., 2004; 
Lerman et al., 2015; Malaiyandi, Goodz, Sellers, & Tyndale, 2006; Schnoll et al., 2009). CYP2A6 activity is 
indeed induced by estradiol, leading to increased nicotine metabolism (Higashi et al., 2007) and women 
are more likely to be normal metabolizers than slow metabolizers (Chenoweth et al., 2014; Lerman et 
al., 2015), especially when receiving estrogen-based hormonal therapy (Benowitz, Lessov-Schlaggar, 
Swan, & Jacob, 2006). The influence of sex on the effectiveness of smoking cessation treatment has 
been largely described. A meta-analysis of 14 studies comparing smoking cessation rate in men and 
women receiving nicotine patches reported a significantly lower rate of abstinence in women (Perkins & 
Scott, 2008). Men were also found to have a significantly better abstinence rate with the combination 
varenicline-bupropion than with varenicline alone, whereas women had a similar response to both 
treatments (Potter, 2014; Rose & Behm, 2014). It has therefore been suggested that women benefit 
more than men from varenicline alone and thus the addition of bupropion to varenicline would not 
improve the response in women (Gorelick, 2015; Rose & Behm, 2015). Interestingly, varenicline 
compared to nicotine patches doubled the odds of abstinence at the end of a 4-week treatment in an 
exploratory short-term double-blind randomized trial among women smokers (Gray et al., 2015). In a 
longer term, at 12 weeks, women had greater quit rates when receiving varenicline compared to NRT in 
a study involving almost 7000 smokers (Walker et al., 2016). Very recently a meta-analysis of 32 studies 
representing more than 14 000 smokers reported a greater efficacy in women taking varenicline 
compared to transdermal nicotine or bupropion. In men, no difference was shown between the three 
treatments (Smith et al., 2016). 
Several single nucleotide polymorphisms (SNP) in the CYP2A6 gene that affect enzyme activity have 
been characterized (Goodz & Tyndale, 2002; Mwenifumbo & Tyndale, 2007). One of the most studied 
allele is the rs1801272 (479T>A, Leu160His, CYP2A6*2) (Ray, Tyndale, & Lerman, 2009; Yamano, 
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Tatsuno, & Gonzalez, 1990). It leads to a predicted CYP2A6 activity between 40 and 50% of the normal 
activity, or less than 40% if two mutated alleles A are present (Malaiyandi et al., 2006). Thus, individuals 
carrying one or two CYP2A6*2 alleles are considered slow nicotine metabolizers (Benowitz, Swan, Jacob, 
Lessov-Schlaggar, & Tyndale, 2006). Another common polymorphism, the rs28399433 (CYP2A6*9, -
48T>G) located in the TATA box of the 5’ flanking region of the CYP2A6 gene has been identified. The 
activity of the mutated TATA was reduced by 55% when compared to the wild allele and was shown to 
reduce mRNA expression and enzyme activity. (Haberl et al., 2005; Pitarque et al., 2001). 
The primary objective of our post-hoc analysis of data from usual clinical care was to explore the 
influence of nicotine metabolism determined by the nicotine-metabolite ratio and of sex on the 
response to NRT and varenicline. Based on previous clinical trials (Gray et al., 2015; Lerman et al., 2015; 
Perkins & Scott, 2008), we hypothesized that nicotine normal metabolizers and women would benefit 
more from varenicline. The second objective was to compare the influence of nicotine metabolism 
determined phenotypically by the nicotine-metabolite ratio and genetically by the CYP2A6 rs1801272 
and rs28399433 polymorphisms on the response to NRT and varenicline.  
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METHODS 
Study design and participants 
The original aim of this clinical and pharmacogenetic study was to examine the influence of smoking 
cessation on the activity of CYP1A2 isoform (Dobrinas, Cornuz, et al., 2011). For this purpose it included 
smokers from the general population wishing to participate in a smoking cessation program. This 
program offered a 3-month study period (5 visits every week from week 0 to week 4, 4 visits every 2 
weeks from week 4 to week 12) comprising smoking-cessation counseling and pharmacological 
treatment prescription (combined nicotine replacement therapies: patches, gums and/or inhaler or 
varenicline) and a 6-month concluding visit. Details of the inclusion and exclusion criteria as well as 
clinical measures have been previously described (Dobrinas, Cornuz, et al., 2011). Blood sampling 
performed before the quit date was used to measure the nicotine-metabolite ratio. Abstinence was 
assessed during the follow-up by self-declaration and by measuring expired CO levels (Micro 
Smokerlyzer; Bedfont Scientific, Rochester, England). Abstinence was confirmed if CO level was less than 
10 parts per million (ppm). The number of cigarettes smoked between two visits was also recorded. The 
study was approved by the ethics committee of the Lausanne University Medical School and by the 
Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland). Written informed consent was 
obtained from all participants.  
 
Treatment 
After a counseling session with a clinician, participants chose to receive either varenicline or combined 
nicotine replacement therapies (patches, gums and/or inhaler) in agreement with the clinician. NRT and 
varenicline were prescribed according to the manufacturers’ information, to guidelines for smoking 
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cessation (The 2008 PHS Guideline Update Panel, 2008), and to patients’ preferences. Main counter-
indications included cardiovascular diseases (unstable angina pectoris, recent myocardial infarction) or 
skin disorders (eg. psoriasis, chronic dermatitis, urticaria) for NRT, and depression, past antidepressant 
treatments or other psychiatric diseases for varenicline. NRT formulations and dosing were chosen 
according to the nicotine dependence score measured by the Fagerström test for nicotine dependence 
(FTND) ranging from 0 to 10 (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). For instance, 
patients with a high dependence score (8 to 10) were prescribed with high concentration patches, 
combined with other NRT formulations (gums and/or inhaler). In patients with low dependence scores 
(0 to 3), one NRT formulation could be sufficient (low dose patches or gums/inhaler). NRT dosing was 
gradually decreased each month, for total treatment duration of 12 weeks. Varenicline was prescribed 
starting from one week before the quit date (0.5 mg once daily on days 1-3 and 0.5 mg twice daily on 
days 4-7), then continued with 1 mg twice daily for a total of 12 weeks. The pharmacological treatment 
was proposed for 12 weeks free-of-charge and treatments were delivered at each visit. Varenicline 
treatment but not combined NRT could be proposed for 12 supplementary weeks as recommended in 
the manufacturer’s information. 
If needed and with the approval of a clinician, a switch of treatment was allowed during the study. As 
the aim of the present study was to compare the effectiveness on smoking cessation of these two 
treatments, data from subjects who switched from one treatment group to another were excluded from 
the analysis (Figure 1). 
 
Nicotine-metabolite ratio 
Cotinine and 3’-hydroxycotinine plasma levels were simultaneously measured by an ultra performance 
liquid chromatography-tandem mass spectrometry method while participants were smoking ad libitum 
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at the beginning of the study (Dobrinas, Choong, et al., 2011). Subjects were phenotypically considered 
slow metabolizers if nicotine-metabolite ratio was inferior to 0.26 and normal metabolizers if nicotine-
metabolite ratio was higher or equal to 0.26 as previously described (Schnoll et al., 2009). The cut-off 
was set to the originally determined value of 0.26 in (Schnoll et al., 2009).  
 
Genotyping 
CYP2A6 SNPs were obtained using the CardioMetaboChip, a custom Illumina iSelect genotyping array 
designed to test DNA variation of over 200,000 SNPs from regions identified by large scale meta-
analyses of genomewide association studies for metabolic and cardiovascular traits. 3642 customized 
SNPs covering pharmacokinetic genes were added in the Cardiometabochip (Lubomirov, Csajka, & 
Telenti, 2007; Lubomirov et al., 2010), among which 8 SNPs from the CYP2A6 gene (rs5031016, 
rs8192730, rs1809810, rs1801272, rs28399453, rs28399454, rs28399433, rs2892625). Four SNPs were 
excluded from analysis due to a very low minor allele frequencies (MAF<0.005) as reported in European 
population (rs5031016, rs8192730, rs1809810, rs28399454) (Flicek et al., 2014). The rs28399453 
polymorphism is not reported to influence CYP2A6 activity and was thus excluded from analysis. Quality 
control excluded samples from the analysis if sex was inconsistent with genetic data from X-linked 
markers, genotype call rate less than 0.96 or Gene Call score less than 0.15. The SNP rs2892625 was 
excluded from analysis due to a Gene Call score < 0.15. The two polymorphisms rs1801272 and 
rs28399433 were in Hardy Weinberg Equilibrium (p=0.68 and p=0.65, respectively) and were used for 
determining CYP2A6 genotype. In the sample analysis, individuals were homozygous non-mutated (TT) 
or heterozygous (TA) for the SNP rs1801272 and individuals were homozygous non-mutated (TT) or 
heterozygous (TG) for the SNP rs28399433. There were no homozygous mutated for any of the SNPs in 
the sample analysis. Subjects were classified as slow metabolizers if they were heterozygous for the 
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SNPs rs1801272 or rs28399433, or for both SNPs according to results previously published (Benowitz, 
Swan, et al., 2006; Haberl et al., 2005; Pitarque et al., 2001). The homozygous non-mutated for both 
SNPs were defined as normal metabolizers. GenomeStudio Data Analysis Software was used to export 
results generated by Illumina CardioMetaboChip.  
 
Statistical analysis 
In this work, total smoking cessation and partial smoking reduction is used to evaluate response to 
nicotine replacement therapy or varenicline. Response to treatment was defined by the absence of 
relapse (i.e. when the reduction in cigarettes per day (CPD) consumption relative to the week before the 
study was not reached anymore).  
- Exploratory analysis for selection of thresholds 
An exploratory analysis was first conducted to find the most appropriate threshold in CPD reduction 
defining partial smoking reduction. The week before the study and at each visit, participants self-
reported the number of cigarettes per day or over the period between two visits. For non-daily smokers, 
the number of cigarettes smoked over the period between 2 visits was divided by the number of days of 
the period to calculate CPD. Overall, there was a concordance between the CPD and the CO levels 
recorded (r2=0.49, p < 0.01). For each subject and each visit the reduction in the number of CPD relative 
to the number of CPD the week before the study was calculated. A binary variable was defined as 
follows: status=0 if the threshold of CPD reduction was reached, status=1 if the threshold was not 
reached anymore (i.e relapse). By varying the potential thresholds between 50% and 100% in the 
reduction of CPD, 51 variables status were coded for each subject at each visit. Then, for each threshold 
of reduction and each subject, a time-to-event variable was determined as the duration from the first 
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visit when the threshold was reached to the time when the threshold was not reached anymore, or to 
the end of follow-up. Consequently, data from the visits during which the threshold was not already 
reached and participants who never reached the threshold were excluded from analysis (Figure 1). Fifty-
one hazard-ratios (HR) representing the risk of relapse (for each one of 51 potential thresholds) were 
estimated to assess the effect of treatment (varenicline vs. nicotine replacement therapy) by adjusting 
for nicotine-metabolite ratio (slow metabolizers vs. normal metabolizers) and sex (men vs. women) in 
fitting a Cox proportional hazard regression model. 
HR and the 95%CI are presented in Figure S1. With increasing threshold, the number of subjects 
included in each analysis decreased and the number of relapses increased. From 90% to 100% of CPD 
decrease, the 95%CI of the HR was the smallest, stable, and mostly below the value of 1. Two thresholds 
of reduction: the first one considering total abstinence: diminution of 100%, and the second one 
considering a partial reduction of smoking: diminution of 90%, were therefore selected for further 
analysis. 
- Relapse analysis for a total cessation and a partial reduction of CPD 
Participants were considered as relapser if their reduction in CPD consumption became lower than the 
predefined threshold and as no relapser if they maintained the predefined threshold of CPD reduction 
during the overall period of follow-up. In the overall sample, Chi-squared tests evaluated the 
distributions of treatment group, nicotine metabolism (phenotypically determined by the nicotine-
metabolite ratio) and sex among the relapsers and non relapsers as well as the distribution of the 
normal metabolizers and slow metabolizers among men and women. The cumulative probability of 
maintaining the selected threshold of CPD reduction by treatment group in the overall sample analysis 
was assessed using Kaplan-Meier survival analyses with subsequent Log-Rank tests. 
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Multivariate Cox proportional hazards regression models were carried out to obtain the HR of relapse 
and its 95%CI for the treatment (varenicline vs. NRT) in the overall sample and in subgroups: normal 
metabolizers, slow metabolizers, men and women. The analyses were adjusted for nicotine-metabolite 
ratio, nicotine-metabolite ratio-by-treatment interaction, sex, age of onset for smoking and the number 
of CPD usually smoked in the overall sample. In normal and slow metabolizers, the analyses were 
adjusted for sex, age of onset for smoking and the number of CPD usually smoked. In men and women, 
the adjustment was made by the nicotine-metabolite ratio, the nicotine-metabolite ratio-by-treatment 
interaction, the age of onset for smoking and the number of CPD usually smoked. All statistical analyses 
were performed using the R software (v. 3.1.2, http://www.r-project.org). Results were considered 
statistically significant if p ≤ 0.05 (two-tailed). Finally, with regards to the Cox regression, proportional 
hazard assumption was verified using the Grambsch Therneau test and results were satisfactory 
(Grambsch & Therneau, 1994). 
- Influence of the genetically determined nicotine metabolism on the treatment response 
To investigate the effect of nicotine metabolisation effect on risk of relapse, the association of nicotine 
metabolism genetically determined (normal and slow metabolizers) versus the relapse status (relapser 
and no relapser) was first assessed using Chi-squared test. Then, the sample was stratified between 
normal metabolizers and slow metabolizers to obtain the HR of relapse and its 95% CI for the treatment 
(varenicline vs. NRT) in two subgroups using Cox proportional hazards regression models by adjusting for 
sex, age of onset for smoking and the number of CPD usually smoked. 
  
15 
 
RESULTS 
Study participants and analysed sample 
211 smokers were recruited for a smoking cessation study and 194 subjects fulfilled the inclusion 
criteria. 153 and 164 participants were analyzed for the 100% (total cessation) and for the 90% (partial 
decrease) of CPD decrease, respectively (Figure 1).  
Participants did not differ in any of the examined variables except in the age of onset for smoking with a 
lower age in the varenicline compared to the NRT group (Table 1). In addition, in the analysis of a 90% of 
CPD decrease, the number of usually smoked CPD was significantly smaller in the NRT group than in the 
varenicline group (n=20 CPD and n=24 CPD respectively, p=0.03), but there was no significant difference 
in the number of smoked CPD the week before the study. Separate data between male and female are 
shown in Table S1. Of note, the number of usually smoked cigarettes per day is significantly different 
between NRT and varenicline in males but not in females, which was taken into account in the statistical 
analysis. Although compliance cannot be ascertained, all participants were asked about the actual intake 
of varenicline or nicotine patches, gums or inhalers at each visit. 
When phenotypically determined, women were more likely to be normal metabolizers than slow 
metabolizers in the analyses for a 100% and a 90% of CPD decrease (Table 2, p=0.03 and p=0.01, 
respectively).  
 
Relapse analysis for a total cessation and a partial reduction of CPD 
For the decrease of 100% and 90%, relapse was significantly associated with the treatment (Table 3, 
p=0.04 and p=0.02, respectively), NRT associated with more cases of relapse. The Kaplan-Meier estimate 
of the probability of maintaining the threshold was significantly higher for varenicline when compared 
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to NRT for a 90% of CPD decrease (Figure 2B, p=0.014). The estimate was also higher for varenicline but 
not significant for a 100% of CPD decrease (Figure 2A, p=0.054). 
The multivariate Cox regression predicted in the overall sample that participants treated with 
varenicline had a significant lower risk of relapse for a 90% of CPD decrease (Table 4, HR=0.34, 
95%CI=[0.13-0.90]) and a non-significant lower risk of relapse for a 100% of CPD decrease (HR=0.49, 
95%CI=[0.22-1.07]). In the nicotine normal metabolizers determined by phenotyping, varenicline was 
significantly better for a partial decrease (HR=0.33, 95%CI=[0.12-0.89]) and non-significantly better 
(HR=0.45, 95%CI=[0.20-1.0]) for a total cessation. In women, the risk of relapse with varenicline was 
significantly lower for a partial decrease (HR=0.20, 95%CI=[0.04-0.91]) but non-significantly lower for a 
total cessation (HR=0.38, 95%CI=[0.14-1.0]). No treatment was found significantly better in slow 
metabolizers determined by phenotyping for a total cessation and a partial decrease (HR=0.70, 
95%CI=[0.28-1.75] and HR=0.48, 95%CI=[0.14-1.7], respectively) and in men, for a total cessation and a 
partial decrease (HR=0.70, 95%CI=[0.20-2.5] and HR=0.55, 95%CI=[0.15-2.0], respectively). 
 
Comparison of the influence of the nicotine metabolism determined either phenotypically or 
genetically, on treatment response 
The frequency of slow metabolizers was found to be much lower than the normal metabolizers when 
classifying participants according to CYP2A6 genotype as compared to the classification based on 
phenotype (Table 1).These differences could probably be explained by the fact that classification based 
on phenotyping includes environmental factors, while genotyping was based on two SNPs only, whereas 
other mutations are possibly contributing to a slow metabolizer phenotype. 
17 
 
For a partial decrease, the multivariate Cox regression predicted a similar significant lower risk of relapse 
with varenicline in the normal metabolizers determined by genotyping when compared to the normal 
metabolizers determined by phenotyping (Table 4, HR=0.42, 95%CI=[0.18-0.94] and HR=0.33, 
95%CI=[0.12-0.89], respectively). But for a total cessation, the lower risk of relapse with varenicline in 
the normal metabolizers determined by genotyping was significant (HR=0.50, 95%CI=[0.26-0.98]) 
however it was non-significant in the normal metabolizers determined by phenotyping (HR=0.45, 
95%CI=[0.20-1.0]). Concerning the slow metabolisers no treatment was found significantly better in the 
case of a genotype-based and phenotype-based determination (HR=0.81, 95%CI=[0.06-10.2] and 
HR=0.48, 95%CI=[0.14-1.7], respectively) for a partial decrease and a total cessation (HR=1.05, 
95%CI=[0.22-5.1] and HR=0.70, 95%CI=[0.28-1.75], respectively).   
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DISCUSSION 
It has recently been shown that nicotine normal metabolizers (phenotypically determined by the 
nicotine-metabolite ratio) have better quit rates with varenicline compared to nicotine patches (Lerman 
et al., 2015). To our knowledge, the present study is the first to replicate this finding in usual clinical care 
data, using both phenotyping and genotyping tests. Varenicline response was superior to NRT in 
phenotype-based normal metabolizers in the case of a partial reduction. The finding that women 
smokers have higher response with varenicline over NRT for a partial reduction are in accordance with 
other recent findings (Gorelick, 2015; Gray et al., 2015; Rose & Behm, 2015). The influence of sex in the 
effectiveness of the smoking cessation agent is now well acknowledged (McKee & Weinberger, 2015; 
Weinberger, Smith, Kaufman, & McKee, 2014). Because CYP2A6 mRNA is induced by estradiol (Higashi 
et al., 2007), women and especially premenopausal women, may metabolize nicotine and cotinine faster 
than men (Benowitz, Lessov-Schlaggar, et al., 2006). Supposedly, with nicotine being rapidly 
metabolized in women, the pharmacological effect of NRT on withdrawal symptoms is lower, which is in 
agreement with the reported lower success rate with nicotine patches (Perkins & Scott, 2008). No 
difference was observed in treatment success in slow metabolizers and in men. 
Of note, in normal metabolizers genetically determined by the rs1801272 and rs28399433 mutations, 
the multivariate Cox regression model showed similar response to treatment for a partial CPD decrease 
compared to the same subgroup phenotypically determined. For a total abstinence, response to 
treatment was similar in normal metabolizers genetically or phenotypically determined, except a lack of 
statistical power in the analysis to observe a significant result in the phenotype-based normal 
metabolisers. The similarity of the result could be explained, at least in part, by the demonstrated 
influence of these mutations on CYP2A6 activity (Haberl et al., 2005; Malaiyandi et al., 2006; Pitarque et 
al., 2001). On the other hand, it can be assumed that the prediction of CYP2A6 activity based on 
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nicotine-metabolite ratio is more accurate, as it integrates both genetic factors (taking into account all 
genetic variations and not only one mutation) and environmental factors (e.g. induction by estrogens). 
In the overall sample analyzed, the probability of maintaining a diminution of 90% of smoked cigarettes 
per day over 6 months was higher in the varenicline group than in the NRT group, while a trend was 
found when using a total abstinence as threshold. These results are not in agreement with the 
equivalent efficacy of varenicline and combined NRT reported in a meta-analysis (Cahill et al., 2013) 
comparing both treatments. It has to be stressed that the sample size in the present study was limited 
and the results should therefore be replicated. However, a special emphasis should be put on the 
selection of outcomes, which differ between the present and the meta-analysis (Cahill et al., 2013): time 
during which a threshold of total cessation or partial reduction in CPD is maintained vs. continuous or 
prolonged abstinence at least 6 months from the start of the treatment, respectively.  
In the present study, the analyses considered an absolute abstinence (reduction of 100%) as well as a 
partial reduction in CPD (90% reduction). Both thresholds gave essentially similar results. It should be 
mentioned that reduction in CPD consumption (instead of cessation) does not cancel health risks: a 
significantly higher risk of dying, especially from ischaemic heart disease and lung cancer, was observed 
in men and women smoking 1 to 4 cigarettes per day compared to never-smokers (Bjartveit & Tverdal, 
2005). Thus, changes in CO and cotinine plasma levels consistently showed smaller reduction than CPD 
(Stead & Lancaster, 2007) due to the phenomenon of oversmoking: smokers involuntarily increase the 
number and depth of inhalations from the remaining cigarettes to obtain the necessary nicotine 
quantity (Sadowski, Clair, & Cornuz, 2015). This phenomenon is also observed in the present study: for 
the analysis of 90% of CPD decrease when compared to the NRT group, the number of usually smoked 
CPD is significantly lower in the varenicline group while there is no difference in cotinine and 3’-
hydroxycotinine plasma levels. On the other hand, consumption reduction seems not to discourage 
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smokers unmotivated to a project of total abstinence and can even encourage them when it is 
supported by NRT (Hughes & Carpenter, 2006; Stead & Lancaster, 2007). Gradual reduction before the 
quit day appears to be associated with equivalent smoking cessation rates compared with abrupt 
cessation (Lindson-Hawley, Aveyard, & Hughes, 2012). Sustained reduction was defined as reduction in 
50% or more of the baseline reported cigarettes consumption in some industry sponsored trials (Moore 
et al., 2009). In this work, when the reduction in cigarette consumption was below 90% of baseline, 
more subjects reached this objective, the number of relapses was lower and Cox regressions provided a 
very large HR 95%CI. We hypothesize that decreasing the cigarettes consumption by less than 90% of 
baseline value is a more feasible objective, leading to the difference between treatment responses 
being smaller with a large HR 95%CI.  
Several limitations of the present study must be discussed. Firstly, this clinical and pharmacogenetic 
study was not designed for the purpose of the present evaluation. However the valuable comparison of 
varenicline and NRT effectiveness by nicotine metabolism and sex obtained with clinical trials previously 
published deserved an investigation in the natural context of a smoking cessation program as proposed 
in tobacco consultation. Secondly the analysis used a unique longitudinal dataset with rather small 
sample size per treatment group and no corrections for multiple testing were performed. Analyses 
should therefore be repeated in a larger cohort to confirm the influence of sex and nicotine metabolism 
on the response to varenicline and nicotine replacement therapy. However, the present findings are in 
agreement with a recently published study (Lerman et al., 2015), and it is remarkable that similar results 
were obtained when examining the influence of CYP2A6 activity based both on phenotyping and 
genotyping methods. Thirdly, this study was not randomized and it is not known whether the choice of 
the treatment by the participant could have an influence on the results. However the significant 
difference in age of onset for smoking and in number of usually smoked cigarettes per day between the 
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varenicline and the NRT group has been taking into account in the multivariate analysis by the 
correction with these two variables.  
In summary, treatment of nicotine dependence is very challenging and can be hampered by the lack of 
motivation, environmental factors or ineffective pharmacological treatment (Fiore & Baker, 2011). In the 
present work, we showed that nicotine normal metabolizers are more likely to benefit from varenicline 
over NRT in usual clinical care data. Women who are reported to achieve a lower abstinence rate with 
NRT than men may have better success in smoking cessation with varenicline treatment. Future studies 
should also address the question on whether normal metabolizers and women would equally benefit, 
instead of varenicline, from higher nicotine doses. Because of the scarcity of existing data, our results 
contribute valuably to the extensive process of tailoring smoking cessation strategy.  
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Table 1: Description of the population included in the analysis of a 100% and a 90% of CPD decrease 
 Analysis for a 100% of CPD decrease Analysis for a 90% of CPD decrease 
Characteristic 
NRT 
(N=82) 
Varenicline 
(N=71) 
p 
NRT 
(N=87) 
Varenicline 
(N=77) 
p 
 N % N %  N % N %  
Men 43 52 33 46 0.57
2
 43 49 37 48 0.9
2
 
Nicotine NM based on NMR 52 63 43 61 0.8
2
 56 64 47 61 0.8
2
 
Nicotine NM based on genotyping 77 94 66 93 1
2
 76 87 65 84 0.75
2
 
Treatment duration
4
      0.27
2
     0.21
2
 
Less than or equal to 2 months 36 44 24 34  40 46 27 35  
More than 2 months 45 55 46 65  46 53 49 64  
Subjects with smokers at home 20 24 19 27 0.9
2
 20 23 20 26 0.8
2
 
Ethnicities 
    0.9
3
     0.9
3
 
Caucasian 79 97 68 97  84 97 74 97  
African/African-American 2 2 1 1  2 2 1 1  
Arabic 0 0 1 1  0 0 1 1  
Others 1 1 1 1  1 1 1 1  
 Mean SD Mean SD  Mean SD Mean SD  
Age, years 41 11 38 10 0.1
1
 41 11 39 11 0.2
1
 
Cotinine before the quit date, ng/ml 271 140 264 127 0.95
1
 269 138 262 124 0.96
1
 
3’-hydroxycotinine before the quit 
date, ng/ml  
87 50 89 51 0.69
1
 87 50 88 50 0.76
1
 
Age of onset for smoking, years 19 7 16 3 0.009
1
 19 7 17 4 0.02
1
 
Number of usually smoked CPD 20 8 22 10 0.07
1
 20 8 24 11 0.03
1
 
Number of smoked CPD during the 19 8 20 10 0.63
1
 19 8 21 11 0.37
1
 
week before the study 
Number of previous quit attempts 1.6 0.9 1.7 0.8 0.6
1
 1.6 0.9 1.7 0.8 0.7
1
 
FTND
6
 5 2.1 5
5
 2.0
5
 0.8
1
 5 2.2 5
5
 2.0
5
 0.7
1
 
CPD: Cigarettes Per Day, NRT: Nicotine Replacement Therapy, NM: Normal Metabolizer, NMR: Nicotine-metabolite Ratio, 
FTND: Fagerström Test for Nicotine Dependence  
1
: Wilcoxon rank sum test 
2
: Chi-squared test 
3
: Fisher exact test 
4
: For both analyses, the treatment duration was unknown for one subject in the NRT group and one subject in the 
varenicline group. 
5
: Missing data for one individual 
6
: Fagerström Test for Nicotine Dependence score ranged from 0 to 10. 
 
1 
 
Table 2: Distribution between nicotine metabolism and sex  
 Analysis for a 100% of CPD decrease Analysis for a 90% of CPD decrease 
Sex NM
1
 SM
1
 p
2
 NM
1
 SM
1
 p
2
 
       
Men 40 36 0.03 42 38 0.01 
Women 55 22  61 23  
CPD: Cigarettes Per Day, NM: Normal Metabolizer, SM: Slow Metabolizer 
1 phenotypically determined by the nicotine-metabolite ratio 
2 Chi-squared test 
 
 
Table 3: Distribution of study participants according to the binary variable: no relapse (status = 0) and 
relapse (status = 1), treatment, sex, nicotine metabolism phenotypically determined and nicotine 
metabolism genetically determined. 
 Analysis for a 100% of CPD decrease Analysis for a 90% of CPD decrease 
Variables No relapse Relapse p No relapse Relapse p 
 N % N %  N % N %  
Treatment     0.041     0.021 
NRT 47  57 35  43  61  70 26  30  
Varenicline 53  75 18  25  67  87 10  13  
Sex     0.341     0.691 
Men 53 70 23  30  64  80 16  20  
Women 47  61 30  39  64  76 20  24  
Nicotine metabolism 
based on phenotype2 
    
0.841 
    
0.461 
NM 61  64 34  36  78  76 25  24  
SM 39  67 19  33  50  82 11  18  
Nicotine metabolism 
based on genotype3 
    
14 
    
11 
      NM 86  66 45 34  110  78 31 22  
SM 14  64 8  36  18  78 5   22  
CPD: Cigarettes Per Day, NRT: Nicotine Replacement Therapy, NM: Normal Metabolizer, SM: Slow 
Metabolizer 
1 Chi-squared test 
2 Phenotypically determined by the nicotine metabolic ratio (slow metabolizer if nicotine-metabolite 
ratio < 0.26 and normal metabolizer if nicotine-metabolite ratio >=0.26) 
3 Genetically determined by the genotyping of CYP2A6 rs1801272 and rs28399433. 
4 Fisher exact test 
 
1 
 
Table 4: Adjusted hazard ratios of relapse for a 100% and a 90% of CPD decrease in the overall sample 
and in subgroups: normal metabolizers, slow metabolizers, men and women. 
 Analysis for a 100% of CPD decrease Analysis for a 90% of CPD decrease 
Analysis groups N Hazard 
Ratio 
95%CI N Hazard 
Ratio 
95%CI 
In overall sample       
Treatment (V vs. NRT) 71 vs. 82 0.49 0.22-1.07 77 vs. 87 0.34 0.13-0.90 
In NM
 
(phenotyping)
1
       
Treatment (V vs. NRT) 43 vs. 52 0.45  0.20-1.0 47 vs. 56 0.33 0.12-0.89 
In SM
 
(phenotyping)
1       
Treatment (V vs. NRT) 28 vs. 30 0.70  0.28-1.75 30 vs. 31 0.48 0.14-1.7 
In NM
 
(genotyping)
2
       
Treatment (V vs. NRT) 59 vs. 72 0.50  0.26-0.98 65 vs. 76 0.42 0.18-0.94 
In SM
 
(genotyping)
2
       
Treatment (V vs. NRT) 12 vs. 10 1.05  0.22-5.1 12 vs. 11 0.81  0.06-10.2 
In men       
Treatment (V vs. NRT) 33 vs. 43 0.70  0.20-2.5 37 vs. 43 0.55 0.15-2.0 
In women       
Treatment (V vs. NRT) 38 vs. 39 0.38  0.14-1.0 40 vs. 44 0.20 0.04-0.91 
CPD: Cigarettes Per Day, V: Varenicline, NRT: Nicotine Replacement Therapy, SM: Slow Metabolizer, NM: Normal 
Metabolizer 
1. Phenotypically determined by the nicotine-metabolite ratio (NMR) (SM if NMR < 0.26 and NM if NMR >=0.26) 
2. Genetically determined by the CYP2A6 rs1801272 andrs28399433 genotyping. 
 
211 recruited for the study 
194 included in the study 
11 excluded 
     9 had  an unstable medical condition 
     1 presented high levels of alcohol consumption  
     1 was consuming cannabis 
6 withdrew or declined to participate after screening 
153 analysed  for a 100% of CPD decrease 
         N= 71 in the varenicline group 
         N= 82 in the NRT group  
41 excluded from the analysis of a 100% of CPD decrease 
     30 never reached -100% of CPD decrease 
     6 switched treatment 
     4 stopped treatment 
     1 NMR not available at week 0 
30 excluded from the analysis of a 90% of CPD decrease 
     17 never reached -90% of CPD decrease 
     8 switched treatment 
     4 stopped treatment 
     1 NMR not available at week 0 
164 analysed for a 90% of CPD decrease 
         N= 77 in the varenicline group 
         N=  87 in the NRT group 
Figure 1: Flow chart for selection of patients 
 
CPD: cigarettes per day 
NMR: nicotine-metabolite ratio 
NRT: nicotine replacement therapy 
Number of participants at risk 
Varenicline      71     49          41      41     33 
Nicotine      82     50          35      34     18 
p = 0.054* 
Figure 2: Kaplan-Meier estimates of probability of maintaining the threshold of -100% (A), and of -90% (B) in the overall analysis sample. Each cross 
on the curves represents a lost to follow-up.  
A.  B.  
p = 0.014* 
*Log-Rank test 
Number of participants at risk 
Varenicline        77      59      46     41     27 
Nicotine        87      65      40     36     28 
Supplemental Table S1: Description of the population included in the analysis of a 100% and a 90% of 
CPD decrease by sex 
 
 
 
Analysis for a 100% of 
CPD decrease 
In males 
Analysis for a 90% of 
CPD decrease 
In males 
Analysis for a 100% of 
CPD decrease 
In females 
Analysis for a 90% of 
CPD decrease 
In females 
Characteristic 
N
R
T 
(N
=4
3
) 
V
ar
e
n
ic
lin
e
 
(N
=3
3
) 
p 
N
R
T 
(N
=4
3
) 
V
ar
e
n
ic
lin
e
 
(N
=3
7
) 
p 
N
R
T 
(N
=3
9
) 
V
ar
e
n
ic
lin
e
 
(N
=3
8
) 
p 
N
R
T 
(N
=4
4
) 
V
ar
e
n
ic
lin
e
 
(N
=4
0
) 
p 
 N N  N N  N N  N N  
Nicotine NM based on 
NMR 
23 17 1
2
 23 19 1
2
 29 26 0.7
2
 33 28 0.8
2
 
Nicotine NM based on 
genotyping 
40 30 1
3
 40 34 1
3
 32 29 0.7
2
 36 31 0.8
2
 
Treatment duration
4
    0.6
2
   0.7
2
   0.4
2
   0.3
2
 
Less than or equal to 2 
months 
17 10  17 12  19 14  23 15  
More than 2 months 25 22  25 24  20 24  21 25  
Subjects with smokers at 
home 
9 9 0.7
2
 9 10 0.7
2
 11 10 1
2
 11 10 1
2
 
Ethnicities   0.7
3
   0.7
3
   1
3
   0.8
3
 
Caucasian 42 31  42 35  37 37  42 39  
African/African-
American 
1 1  1 1  1 0  1 0  
Arabic 0 1  0 1  0 0  0 0  
Others 0 0  0 0  1 1  1 2  
 Mean Mean  Mean Mean  Mean Mean  Mean Mean  
(sd) (sd) (sd) (sd) (sd) (sd) (sd) (sd) 
Age, years 
41 
(11) 
38  
(9) 
0.2
1
 
42 
(11) 
39 
(10) 
0.3
1
 
40 
(12) 
38 
(11) 
0.4
1
 
40 
(11) 
39 
(12) 
0.6
1
 
Cotinine before the quit 
date, ng/ml 
288 
(162) 
288 
(124) 
0.6
1
 
288 
(162) 
288 
(120) 
0.6
1
 
252 
(108) 
242 
(126) 
0.7
1
 
251 
(108) 
238 
(125) 
0.5
1
 
3’-hydroxycotinine before 
the quit date, ng/ml  
85 
(53) 
87 
(56) 
0.9
1
 
85 
(53) 
87 
(56) 
0.9
1
 
89 
(48) 
90 
(46) 
0.8
1
 
89 
(47) 
89 
(45) 
0.8
1
 
Age of onset for smoking, 
years 
18  
(6) 
17  
(4) 
0.06
1
 
18  
(6) 
17  
(4) 
0.05
1
 
19  
(8) 
16  
(3) 
0.09
1
 
19  
(8) 
17  
(4) 
0.2
1
 
Number of usually smoked 
CPD 
21  
(9) 
25 
(10) 
0.03
1
 
21  
(9) 
26 
(10) 
0.02
1
 
19  
(7) 
21 
(11) 
0.7
1
 
20  
(7) 
22 
(12) 
0.5
1
 
Number of smoked CPD 
during the week before 
the study 
20  
(9) 
22 
(10) 
0.2
1
 
20  
(9) 
23 
(10) 
0.2
1
 
19  
(7) 
19 
(11) 
0.7
1
 
19  
(8) 
20 
(12) 
1
1
 
Number of previous quit 
attempts 
1.7 
(0.9) 
1.7 
(0.7) 
0.8
1
 
1.7 
(0.9) 
1.6 
(0.7) 
0.7
1
 
1.6 
(0.9) 
1.8 
(0.9) 
0.3
1
 
1.5 
(0.9) 
1.8 
(0.9) 
0.3
1
 
FTND
6
 
4.7 
(2.2) 
5.1 
(2.1)
5
 
0.3
1
 
4.7 
(2.2) 
5.2 
(2.2) 
0.2
1
 
5.4 
(2.0) 
5.0 
(2.1) 
0.4
1
 
5.4 
(2.1) 
5.0 
(2.1) 
0.5
1
 
CPD: Cigarettes Per Day, NRT: Nicotine Replacement Therapy, NM: Normal Metabolizer, NMR: Nicotine-metabolite Ratio, 
FTND: Fagerström Test for Nicotine Dependence
 
1
: Wilcoxon rank sum test
 
2
: Chi-squared test 
3
: Fisher exact test 
4
: For both analyses in males, the treatment duration was unknown for one subject in the NRT group and one subject in the 
varenicline group. 
5
: Missing data for one individual 
6
: Fagerström Test for Nicotine Dependence score ranged from 0 to 10 
n subjects 170 168 169 166 164 153
n relapses 13 18 24 27 36 53
V: Varenicline, NRT: Nicotine Replacement Therapy 
Supplemental Figure S1: Hazard ratios (HR) depending on the threshold of cigarettes per day decrease used in each analysis. The line represents the 
hazard ratio; the area represents the 95% confidence interval (95% CI) of the hazard ratio. The sample size (n subjects) and the number of relapse 
are reported for each analysis with a rounding threshold (-50%, -60%, -70%, -80%, -90%, -100%). 
